A case of carbamazepine neurotoxicity following the addition of diltiazem is reported. A patient with previously stable carbamazepine serum concentrations was treated with diltiazem for atrial fibrillation and a rapid ventricular response. After three days on the combined regimen, the patient developed neurological symptoms resulting in hospitalization. After a review of the patient's medication usage and carbamazepine concentrations, an interaction between diltiazem and carbamazepine was suspected. Carbamazepine's elimination appears to have been decreased, resulting in neurotoxicity. The toxicity resolved when the carbamazepine dosage was decreased 62 percent.
LamyPP. Drug interactions and the elderly—a new perspective.Drug Intell Clin Pharm1980; 14: 513–5.
2.
MacpheeGJA, McinnesGT, ThompsonGG, BrodieMJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.Lancet1986; 1: 700–3.
3.
BrodieMJ, MacpheeGJA. Carbamazepine neurotoxicity precipitated by diltiazem.Br Med J1986; 292: 1170–1.
4.
RentonKW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.Biochem Pharmacol1985; 34: 2549–53.
5.
CarrumG, EganJM, AbernathyDR. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.Clin Pharmacol Ther1986; 40: 140–3.
6.
BauerLA, StenwallM, HornJR. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil and diltiazem therapy.Clin Pharmacol Ther1986; 40: 239–42.
